Patient Perspectives in Squamous Cell Carcinoma Clinical Trials
NCT05929547 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-07-03
Summary
Clinical research participation has historically been heavily biased toward specific demographics.
This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell carcinoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of squamous cell carcinoma.
People with squamous cell carcinoma who are invited to take part in clinical research will benefit from the analysis of the data.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-31
- Primary Completion
- 2025-07-31
- Completion
- 2026-07-31
Countries
- United States
Study Locations
More Related Trials
-
Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
NCT03333694 ·Status: TERMINATED ·Phase: PHASE1
-
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
NCT00095641 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
NCT06855212 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma
NCT05845632 ·Status: UNKNOWN
-
Ipilimumab for Head and Neck Cancer Patients
NCT02812524 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
NCT05057247 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
NCT02218164 ·Status: COMPLETED ·Phase: PHASE2
-
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00547157 ·Status: COMPLETED ·Phase: PHASE2
-
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
NCT00009841 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00402545 ·Status: COMPLETED ·Phase: PHASE1
-
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05721755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
NCT05328024 ·Status: RECRUITING
-
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
NCT06236464 ·Status: RECRUITING
-
Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer
NCT01949740 ·Status: TERMINATED
-
Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer
NCT05296135 ·Status: WITHDRAWN
-
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT02277184 ·Status: TERMINATED ·Phase: PHASE1
-
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
NCT00581971 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01154920 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT00458978 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
NCT05213884 ·Status: COMPLETED ·Phase: PHASE2
-
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00098631 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT01316757 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
NCT05068609 ·Status: COMPLETED